EICHORCondition: Kidney Cancer · Sponsor: SWOG Cancer Research Network
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Gulf Coast MBCCOP | Mobile, Alabama, United States | — |
| Providence Hospital | Mobile, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| Arizona Cancer Center at UMC Orange Grove | Tucson, Arizona, United States | — |
| Arizona Cancer Center at University Medical Center North | Tucson, Arizona, United States | — |
| University of Arizona Health Sciences Center | Tucson, Arizona, United States | — |
| Fowler Family Center for Cancer Care | Jonesboro, Arkansas, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| Veteran's Administration Medical Center | Little Rock, Arkansas, United States | — |
| Kaiser Anaheim Medical Center | Anaheim, California, United States | — |
+ 991 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01120249